Aravive Inc (ARAV) Stock Overview
USA - NASDAQ:ARAV - US03890D1081 - Common Stock
ARAV Key Statistics, Chart & Performance
The current stock price of ARAV is 0.0401 USD. In the past month the price decreased by -68.84%. In the past year, price decreased by -97.76%.
ARAV Latest News, Press Relases and Analysis
ARAV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.27 | 397.94B | ||
| AMGN | AMGEN INC | 13.37 | 156.95B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 147.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.63 | 106.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.49 | 69.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.23B | ||
| ARGX | ARGENX SE - ADR | 89.32 | 50.65B | ||
| INSM | INSMED INC | N/A | 35.26B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.57B | ||
| NTRA | NATERA INC | N/A | 26.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.89B | ||
| BIIB | BIOGEN INC | 9.25 | 21.71B |
Related stock screener links
About ARAV
Company Profile
Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The firm's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Company Info
Aravive Inc
River Oaks Tower, 3730 Kirby Drive, Suite 1200
Houston TEXAS 77098 US
CEO: Gail McIntyre
Employees: 23
Phone: 19363551910
Aravive Inc / ARAV FAQ
What does Aravive Inc do?
Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The firm's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
What is the stock price of Aravive Inc today?
The current stock price of ARAV is 0.0401 USD. The price decreased by -13.39% in the last trading session.
Does Aravive Inc pay dividends?
ARAV does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARAV stock?
ARAV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does Aravive Inc belong to?
Aravive Inc (ARAV) operates in the Health Care sector and the Biotechnology industry.
Is Aravive Inc (ARAV) expected to grow?
The Revenue of Aravive Inc (ARAV) is expected to decline by -38.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ARAV Technical Analysis
ARAV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARAV. The financial health of ARAV is average, but there are quite some concerns on its profitability.
ARAV Financial Highlights
Over the last trailing twelve months ARAV reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 59.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| Debt/Equity | 0 |
ARAV Forecast & Estimates
6 analysts have analysed ARAV and the average price target is 0.26 USD. This implies a price increase of 535.91% is expected in the next year compared to the current price of 0.0401.
For the next year, analysts expect an EPS growth of 90.73% and a revenue growth -38.62% for ARAV